Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + PD-1 inhibitor plus first-line chemotherapy in metastatic pancreatic ductal adenocarcinoma
ChiCTR2400086337Phase 3Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of anlotinib and tislelizumab in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
anlotinibtislelizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400086337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086337.